Yeah I tend to agree... something is not sitting right at the moment. Why isn't biota doing a roadshow showing off the renewed interest in relenza and opportunities for LANI.
A few things come to mind... and poor results in RSV/HRV is a maybe. On the other hand they might be in "sensitive" times with regards to licencing and hence the restrained views expressed.
We'll find out all in a few months, getting pretty exciting now that LANI is weeks away from announcing phase III.
BTA Price at posting:
$1.12 Sentiment: Buy Disclosure: Held
